GlassScriptPhysician profile
Bryon Geer
NPI 1942426507
$3,389.92
in general payments reported to CMS, 2019-2025
32 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.99 · 2024: $1,456 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $501.07 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $280.96 | 2024-2025 | |
| Pfizer INC. | $223.14 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.74 | 2024-2025 | |
| Amgen INC. | $183.96 | 2024-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.40 | 2024-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $140.70 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $139.20 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.55 | 2024-2025 | Caplyta |
| Ardelyx, INC. | $130.05 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $127.16 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $125.52 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $124.67 | 2024-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $120.18 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.47 | 2024-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $114.36 | 2024-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $92.31 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $64.24 | 2024-2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Lilly USA, LLC | $57.75 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Sumitomo Pharma America, INC. | $55.68 | 2024-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $53.14 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $39.81 | 2024 | |
| Vanda Pharmaceuticals INC. | $38.54 | 2025 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $28.46 | 2019-2024 | Camzyos |
| Seqirus USA INC | $21.75 | 2025 | Fluad, Flucelvax |
| Medtronic, INC. | $21.62 | 2024 | Intellis Adaptivestim |
| Lundbeck LLC | $19.81 | 2024 | Rexulti |
| Exact Sciences Corporation | $17.34 | 2025 | The Cologuard Plus Collection Kit |
| Dexcom, INC. | $15.37 | 2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $14.97 | 2024 | Edarbi |
| Daiichi Sankyo INC. | $14.64 | 2024 | Injectafer |
| Globus Medical, INC. | $14.36 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryon Geer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.